Biotia

The page answers UTI questions and is written by clinicians and researchers.

The page compares urinalysis, urine culture, PCR, and next-generation sequencing, including what each test can miss.

Precision medicine has been defined by oncology. Next-generation sequencing and AI-powered analytics can bring the same rigor to infectious disease diagnostics.

A negative or “no growth” urine culture does not always mean there is no infection. Standard culture misses up to 1 in 3 UTIs.

Biotia and Hospital for Special Surgery announce a collaboration to advance diagnostics for prosthetic joint infections using pathogen genomics and AI.

Biotia announces an advanced test to treat offering for recurrent urinary tract infections, pairing sequencing-based pathogen detection with clinician care.

The American Medical Association grants a Proprietary Laboratory Analyses code to the BIOTIA-ID Urine next-generation sequencing assay from Biotia.

Biotia deploys BIOTIA-DX Resistance in its CLEP-approved BIOTIA-ID Urine Test, adding antimicrobial resistance prediction after a second CAMDA win.

Open roles at Biotia. Help advance infectious disease diagnostics for hard-to-diagnose infections.

Full-time, on-site role for a NYS-licensed Clinical Laboratory Technologist at Biotia's CLIA/CLEP laboratory in Long Island City, NY. $90,000–$120,000 plus stock options.

Biotia is advancing infectious disease diagnostics for patients managing challenging infections.

Reach the Biotia team for questions about test results, orders, partnerships, billing, or media inquiries.

The company is advancing infectious disease diagnostics for patients managing challenging infections.

Biotia’s privacy policy explains what personal information the company collects, how it uses and shares that information, and the choices people have about their data and account.